Stage 3 multiple myeloma is the most advanced classification of this blood cancer, defined by high levels of a protein called beta-2 microglobulin (at or above 5.5 mg/L) combined with specific genetic abnormalities in the cancer cells, elevated levels of an enzyme called LDH, or both. This staging comes from the Revised International Staging System (R-ISS), which doctors use to estimate how aggressive the disease is and guide treatment decisions.
How Stage 3 Is Determined
Multiple myeloma staging isn’t based on tumor size or spread the way most cancers are staged. Instead, it relies on blood tests and genetic testing of the cancer cells themselves. To qualify as stage 3 under the R-ISS, two conditions must be met simultaneously: beta-2 microglobulin in the blood must be 5.5 mg/L or higher, and the cancer cells must carry at least one high-risk genetic change or the blood must show elevated LDH levels.
Beta-2 microglobulin is a small protein shed by myeloma cells. Higher levels generally indicate a larger volume of cancer in the body. LDH is an enzyme that rises when cells are turning over rapidly, signaling more aggressive disease.
The high-risk genetic changes are identified through a lab test called FISH (fluorescence in situ hybridization), which examines the chromosomes inside myeloma cells. Three specific abnormalities define high risk: a deletion on chromosome 17 (del17p), a swap of genetic material between chromosomes 4 and 14, or a swap between chromosomes 14 and 16. Having even one of these is enough to meet the genetic criteria for stage 3.
Symptoms at This Stage
The hallmark complications of multiple myeloma are summarized by the acronym CRAB: calcium elevation, renal (kidney) problems, anemia, and bone disease. By stage 3, most patients experience at least one of these, and many deal with several at once.
Bone disease is the most common, affecting roughly 68% of symptomatic myeloma patients. Myeloma cells erode bone from the inside, creating weak spots or holes called lytic lesions. These can cause deep bone pain, particularly in the spine, ribs, and hips, and increase the risk of fractures from minor stress. Anemia follows closely, present in about 57% of patients, and causes persistent fatigue, weakness, and shortness of breath. Kidney impairment shows up in around 29% of cases, sometimes significantly enough that filtering capacity drops below 40 mL/min. Elevated calcium, while less common at about 6%, can cause confusion, excessive thirst, nausea, and constipation.
Patients with high calcium levels and bone disease tend to have a notably worse prognosis than those whose main complications are anemia or kidney trouble.
Treatment Approach
Stage 3 myeloma is treated aggressively because the disease is more active and carries higher-risk biology. The backbone of initial treatment is typically a three-drug combination: lenalidomide (an immune-modulating pill), bortezomib (a targeted injection), and dexamethasone (a steroid). This triplet, often called RVd, is given in cycles over several months to reduce the cancer burden as much as possible.
For patients who are healthy enough, usually under 65 with no major organ problems, the next step after initial treatment is an autologous stem cell transplant. This involves collecting your own stem cells, receiving a high dose of chemotherapy to wipe out as much myeloma as possible, then reinfusing the stem cells to rebuild your blood system. Selected patients over 65 can also be candidates if their overall fitness allows it. After transplant, most patients continue on a maintenance medication (typically lenalidomide) indefinitely to keep the disease suppressed.
For patients who aren’t candidates for transplant, treatment continues with additional cycles of combination therapy followed by the same long-term maintenance strategy.
Newer Options for Relapsed Disease
Because stage 3 myeloma is more likely to return or stop responding to initial treatment, newer therapies play an important role. CAR-T cell therapy, which involves engineering a patient’s own immune cells to recognize and kill myeloma cells, has shown strong results in patients whose disease has returned after earlier treatments. In clinical trials, overall response rates have ranged from about 81% to 88%, with complete remission rates between 39% and 74% depending on the specific product and patient population. Progression-free survival with these therapies has ranged from roughly 11 to 20 months in heavily pretreated patients.
Managing Bone and Kidney Complications
Bone-strengthening medications are a standard part of care for anyone with myeloma-related bone disease. These are given as intravenous infusions every three to four weeks alongside cancer treatment. They slow further bone destruction, reduce the risk of fractures, and can help with bone pain. Radiation therapy may also be used to treat painful bone lesions in specific areas.
Kidney function requires close monitoring throughout treatment. Myeloma damages kidneys primarily through abnormal proteins that clog the tiny filtering structures. Staying well hydrated and getting the cancer under control quickly are the most effective ways to protect or restore kidney function. In clinical studies, a meaningful number of patients see their kidney function improve substantially once their myeloma responds to treatment. A complete kidney recovery is defined as filtration rate improving from below 50 to 60 mL/min or higher, something that becomes more achievable when cancer treatment works quickly.
Survival and Prognosis
Stage 3 carries the least favorable prognosis of the three R-ISS stages, primarily because the combination of high tumor burden and aggressive genetic features makes the disease harder to control long term. However, survival statistics have improved meaningfully over the past two decades as new drug classes and treatment strategies have been introduced.
National Cancer Institute data from 2015 to 2021 shows a five-year relative survival rate of about 62% for myeloma that has spread beyond a single site, which applies to the vast majority of myeloma cases. This figure includes all stages and risk levels, so stage 3 patients with high-risk genetics will generally fall below this average, while those whose stage 3 classification is driven more by elevated LDH than by the most dangerous chromosomal changes may do somewhat better.
Individual prognosis varies considerably based on how well the disease responds to initial treatment, overall kidney function, age, and which specific genetic abnormalities are present. The del17p deletion, for instance, is generally considered the most challenging of the three high-risk markers. Patients who achieve a deep response to their first treatment, particularly those who reach a state where no residual disease can be detected at a very sensitive level, tend to have significantly longer remissions regardless of their initial stage.